ClinicalTrials.gg
CompletedNCT01924195Updated Oct 28, 2015

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0302)

A Phase 2 interventional study of Anlotinib and Placebo capsule in Non-small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 13 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-10-28.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing anlotinib in Carcinoma, Non-Small-Cell Lung — 24 open to participants now, 27 under way, 1 of them phase 3. anlotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
11th of 73
117 · median 51
Started
2013
with 1 other
Phase 2
46 of 73
17 open now
Registered
1st of 73
by date
Lead sponsor
9 of 73
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 73 studies testing anlotinib in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment, is one of 2 that started in 2013, is one of 46 in phase 2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

24 of the 73 studies testing anlotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 24 open studies →

Where they have run

About anlotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing anlotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of andvanced non-small cell lung cancer who failed two lines of chemotherapy

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • lung
  • Anlotinib
  • AL3818
  • NSCLC
  • Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. pathology diagnosed with advanced NSCL with ;
  2. Have failed for 2 ;
  3. 18-70years, PS:0-2, of more than 3 months;
  4. Other cytotoxic drugs,radiation therapy,or surgery≥4 weeks;
  5. main organs function is normal;
  6. must be agreed to take measures during the study and within 6 months after end.

Exclusion criteria

Exclusion Criteria:

  1. SCLC(including mixed with NSCLC);
  2. the central cavity of Squamous cell carcinoma and hemoptysis with NSCLC;
  3. patients failed to use the anti-tumor angiogenesis therapy;
  4. patients has many influence factors toward oral medications ;
  5. patients accompanied by symptoms or symptom control for less than two months;
  6. patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade I myocardial infarction, arrhythmias and Class I heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (FBG)>10mmol/L);urine protein≥++,etc.
  7. patients failed to heal wounds or fractures for Long-term;
  8. 4 weeks before enrollment, patients appeared NCI CTC AE grading >1 pulmonary hemorrhage; 4 weeks before enrollment, patients who appeared NCI CTC AE grade> 2 have other parts of the bleeding; patients has a tendency to bleed (eg active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy such as warfarin, heparin or its analogues;
  9. patients occurred venous thromboembolic events within 6 months;
  10. patients has -positive or organ transplantation;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
117 participants (actual)

Study arms

  • Active comparator
    Anlotinib

    Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: Anlotinib

  • Placebo comparator
    Placebo Capsule

    Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent

    Drug: Placebo capsule

Interventions

  • Anlotinib QD po.

  • DrugPlacebo capsule

    Placebo QD po.

06

What researchers measure

Primary outcomes

  1. enhanced CT/MRI scan

    To evaluate the effectiveness of Anlotinib Hydrochloric Capsule by enhanced CT/MRI scan every two cycles. Refer to recist 1.1.

    Time frame: each 42 days up to disease progression

Secondary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    contain Serious Adverse Event To evaluate the safety of Anlotinib by CTC AE 4.0

    Time frame: each 21 days up to intolerance the toxicity(or PD)

07

Study locations

13 sites
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Beijing chest hospital,capital medical university
    Beijing, Beijing 101149, China
  • Xinqiao Hospital, Third Military Medical University
    Chongqing, Chongqing 400037, China
  • Hunan Province Tumor Hospital
    Changsha, Hunan 410013, China
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 215006, China
  • Jilin province tumor hospital
    Changchun, Jilin 130000, China
  • Shandong Province Tumor Hospital
    Jinan, Shandong 250117, China
  • Chest hospital affiliated to Shanghai jiaotong university
    Shanghai, Shanghai 200000, China
  • Shanghai Changhai Hospital
    Shanghai, Shanghai 200433, China
  • West China Hospital,Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Hospital
    Tianjin, Tianjin 300060, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • The first affiliated hospital,zhejiang university
    Hangzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Mar 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2013
First posted
Aug 16, 2013
Start
Aug 2013
Primary completionActual
Mar 2015
CompletionActual
Oct 2015
Last update
Oct 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01924195
Responsible party
Sponsor
First posted
Aug 16, 2013
Start date
Aug 2013
Primary completion
Mar 2015
Completion
Oct 2015
Last update
Oct 28, 2015

Study contacts

Bao hui Han, doctor
principal investigator · Chest hospital affiliated to Shanghai jiaotong university

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion